Chiesi has reported a greater than 9% increase in revenue from 2014 to 2015, with an almost 20% increase in sales of Foster (Fostair) beclamethasone/formoterol inhalers and an unspecified increase in sales of Clenil beclamethasone products. The increase was also partly attributed to the “swift and smooth” integration of Cornerstone Therapeutics,which Chiesi acquired in 2014 and increased sales of Cornerstone’s products, which include Bethkis tobramycin inhalation solution.
In 2015, the company said, it increased R&D spending by more than 28% from €236 million to €300 million, and several regulatory submissions are planned for 2016, including a triple combination therapy for COPD.
Chiesi President Alberto Chiesi commented, “In the latest chapter of a story that just turned 80 years old, we have once again demonstrated our commitment to excellence and our ability to achieve outstanding results, thanks to our agility and ability to both adapt to the dynamic circumstances which characterize our industry, and to be at the cutting-edge of development. . . . 2016 will continue to see Chiesi adhering to its core aim of drug development through its own internal pre-clinical and clinical research programs, but also seeking opportunities to acquire products which are an organic fit with our range of respiratory and special care solutions”.
Read the Chiesi press release.
